Our findings provide us with a novel perspective epigenetic regulation mechanisms underlying CDDP resistance and define that the combination of SMYD2 inhibitor and CDDP may have promise as treatments for patients with CDDP-resistant NSCLC. This evidence concerns the gene SMYD2 and non-small cell lung carcinoma.